Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (Fibro Test) and activity (ActiTest)

Comparative Hepatology

Volumn 3, Issue , 2004, Pages

  Munteanu, Mona ^a   Messous, Djamila ^a   Thabut, Dominique ^a   Imbert Bismut, Françoise ^a   Jouys, Mathieu ^a   Massard, Julien ^a   Piton, Annie ^a   Bonyhay, Luminita ^a   Ratziu, Vlad ^a   Hainque, Bernard ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOCHEMICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; TRIACYLGLYCEROL;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; DIET RESTRICTION; DISEASE ACTIVITY; FEMALE; FOOD INTAKE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; MEAL; POSTPRANDIAL STATE; PREDICTION; PROTEIN BLOOD LEVEL; SCREENING TEST; TRIACYLGLYCEROL BLOOD LEVEL; VOLUNTEER;

EID: 13644263674     PISSN: 14765926     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-5926-3-3     Document Type: Article

References (51)

1. Afdhal NH: Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003, 37:972-974.
2. Dienstag J: The role of liver biopsy in chronic hepatitis C. Hepatology 2002, 36:S152-S160.
3. Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 2001, 344:495-500.
4. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
5. Colloredo G, Guido M, Sonzogni A, Leandro G: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003, 39:239-244.
6. Bedossa P, Dargère D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
7. Poynard T, Ratziu V, Bedossa P: Appropriateness of liver biopsy. Can J Gastroenterol 2000, 14:543-548.
8. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J: Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003, 38:481-492.
9. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, El-Kamary SS, Sulkowski M, Bass EB: Role of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology 2002, 36:S161-S172.
10. The French METAVIR cooperative study group: Intraobserver and interobserver variations in the liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20: 5-20.
11. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
12. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, for the MULTIVIRC group: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
13. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F: Biochemical markers of liver fibrosis in patients infected by Hepatitis C Virus: Longitudinal validation in a randomized trial. J Viral Hepat 2002, 9:128-133.
14. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T: Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002, 97:2419-2425.
15. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, Bricaire F, Katlama C, Poynard T: Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2003, 17: 21-725.
16. Myers RP, de Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T: Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count and the age-platelet index. Dig Dis Sci 2003, 48:146-153.
17. Thabut D, Simon M, Myers RP, Messous D, Thibaut V, Imbert-Bismut F, Poynard T: Noninvasive prediction of fibrosis in patients with chronic hepatitis C [letter]. Hepatology 2003, 37:1220-1221.
18. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G: Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003, 49:450-454.
19. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Portal I, Renou C, Bertrand JJ, Tran A, Rosenthal A, Rotily M, Sattonet A, Ouzan D: Independent prospective multicenter validation of biochemical markers (FibroTest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C [abstract]. Hepatology 2003, 38:188A.
20. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T: Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-230.
21. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, Poynard T: The Predictive values of FibroTest vs APRI for the Diagnosis of Fibrosis in Chronic Hepatitis C [letter]. Hepatology 2004, 39:862-863.
22. Poynard T, Imbert-Bismut F, Ratziu V: Serum markers of liver fibrosis. Hepatology Rev 2004, 1:23-31.
23. Clark GH, Fraser CG: Biological variation of acute phase proteins. Ann Clin Biochem 1993, 30:373-376.
24. Maes M, Cooreman W, Delanghe J, Scharpe S, Wauters A, Neels H, D'Hondt P, Peeters D, Cosyns P, Ranjan R, et al.: Components of biological variation in plasma haptoglobin: relationships to plasma fibrinogen and immune variables, including interleukin-6 and its receptor. Clin Chim Acta 1995, 239:23-35.
25. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, Doutheau D, Klump T, Sala M, Thibaud D, Trepo E, Thabut D, Myers RP, Poynard T: A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002, 1:3-7.
26. Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T: Intra-laboratory analytical variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004, 42:323-333.
27. Morrison B, Shenkin A, McLelland A, Robertson DA, Barrowman M, Graham S, Wuga G, Cunningham KJ: Intra-individual variation in commonly analyzed serum constituents. Clin Chem 1979, 25: 799-1805.
28. Steinmetz J, Panek E, Sourieau F, Siest G: Influence of food intake on biochemical parameters. In Reference values in human chemistry Edited by: Siest. Basle: Karger; 1973:195-200.
29. Statland BE, Winkel P, Bokelund H: Factors contributing to intraindividual variation of serum constituents. 2. Effects of exercise and diet on variation of serum constituents in healthy subjects. Clin Chem 1987, 33:1133-1136.
30. Rifai N, Merill JR, Holly RG: Postprandial effect of a high fat meal on plasma lipid, lipoprotein, cholesterol and apolipoprotein measurement. Ann Clin Biochem 1990, 27: 89-493.
31. Volek JS, Sharman MJ, Gomez AL, Scheett TP, Kraemer WJ: An isoenergetic very low carbohydrate diet improves serum HDL cholesterol and triacylglycerol concentrations, the total cholesterol to HDL cholesterol ratio and postprandial lipemic responses compared with a low fat diet in normal weight, normolipidemic women. J Nutr 2003, 133:2756-2761.
32. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909-916.
33. Delawi D, Meijssen S, Castro Cabezas M: Intra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controls. Clin Chim Acta 2003, 328:139-145.
34. Marin C, Lopez-Miranda J, Gomez P, Paz E, Perez-Martinez P, Fuentes F, Jimenez-Pereperez JA, Ordovas JM, Perez-Jimenez F: Effects of the human apolipoprotein A-I promoter G-A mutation on postprandial lipoprotein metabolism. Am J Clin Nutr 2002, 76:319-325.
35. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Chaput JC, Poynard T: Diagnostic value of biochemical markers (FibroTest) for the prediction of liver fibrosis in patients with chronic alcoholic liver disease (ALD) [abstract]. Hepatology 2003, 38:138A.
36. Ratziu V, Lecalvez S, Imbert-Bismut F, Messous D, Charlotte F, Muntenau M, Poynard T: Diagnostic value of biochemical markers (FibroTest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) [abstract]. Hepatology 2003, 38:112A.
37. Narita T, Kitazato H, Koshimura J, Suzuki K, Murata M, Ito S: Effects of protein meals on the urinary excretion of various plasma proteins in healthy subjects. Nephron 1999, 81:398-405.
38. Miida T, Otsuka H, Tsuchiya A, Okada M: Plasma lipoprotein profiles change significantly during cardiac catheterization. Clin Chem 1998, 44:517-521.
39. Krauss RM, Levy RI, Fredrickson DS: Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia. J Clin Invest 1974, 54: 107-1124.
40. Poynard T, Imbert-Bismut F, Ratziu V, Naveau S, Thabut D, Lebrec D, Halfon P, Zoulim F, Bourliere M, Messous D, Thibaut V, Muntenau M: An overview of biochemical markers' (FibroTest-ActiTest) diagnostic value in chronic liver diseases: a non-invasive alternative to liver biopsy [abstract]. Hepatology 2003, 38:559A.
41. Schumann G, Bonora R, Ceriotti F, Ferard G, Ferrero CA, Franck PFH, et al.: IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37°C. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase [L-Alanine: 2-Oxoglutarate aminotransferase (ALT), EC 2.6.1.2]. Clin Chem Lab Med 2002, 40:718-724.
42. Persijn JP, van der Slik WA: A new method for the determination of γ-glutamyltransferase in serum. J Clin Chem Clin Biochem 1976, 14:421-427.
43. Wahlefeld AW, Herz G, Bernt E: Modification of the Malloy-Evelyn method for a simple, reliable determination of total bilirubin in serum. Scand J Clin Lab Invest 1972, 29(supp 26):Abstract 11-12.
44. Doumas BT, Perry BN, Sasse EA, Straumfjord JV Jr: Standardization in bilirubin assays: Evaluation of selected methods and stability of bilirubin solutions. Clin Chem 1973, 19: 84-993.
45. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, et al.: Consensus of a group of professional societies and diagnostic companies for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/ BCR/ CAP Reference Material (CRM470). International Federation of Clinical Chemistry. Community Bureau of Reference of the commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem 1996, 34:517-520.
46. Albers JJ, Marcovina SM, Kennedy H: International Federation of Clinical Chemistry Standardization Project for Measurement of Apolipoproteins A1 and B. II Evaluation and Selection of Candidate Reference Materials. Clin Chem 1992, 38:658-662.
47. Hintze JL: NCSS 2003 User Guide. Number Cruncher Statistical Systems Kaysville. Uthah; 2003.
48. Landis RJ, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977, 33:159.
49. Kramer MS, Feinstein AR: Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther 1981, 29: 11-123.
50. Thabut D, Imbert-Bismut F, Cazals-Athem D, Moreau R, Messous D, Ratziu V, Munteanu M, Valla D, Lebrec D, Poynard T: Diagnostic value of fibrosis biochemical markers (FibroTest) for the prediction of portal hypertension in liver disease [abstract]. Hepatology 2003, 38:282A.
51. Thabut D, Trabut JB, Le Calvez S, Thibaut V, Massard J, d'Arondel C, Moussalli J, Munteanu M, Imbert-Bismut F, Messous D, Benhamou Y, Ratziu V, Poynard T: Diagnostic value of fibrosis biochemical markers (FibroTest) for the screening of oesophageal varices in patients with chronic liver disease [abstract]. Hepatology 2003, 38:284A.